New Class of Topical Biologics
GX-03 achieves meaningful cytokine modulation without needles, immune suppression, or systemic drug burden.
Inflammatory skin diseases are driven by dysregulation of cytokines produced by tissue-resident cells. By targeting these cytokines topically, we can modulate inflammation at its source while preserving systemic immune function, an approach not possible with current injectable biologics.
Why This Approach Is Needed
- Reduces systemic exposure
- Avoids systemic immune modification
- Focuses on therapeutic activity where eczema originates
- Aligns with patient and provider preferences for alternatives
Turn’s Leadership in the Field
Turn Therapeutics is rapidly emerging as a leader in the development of non-systemic topical biologic therapies.
The company was founded by Bradley Burnam, who developed the PermaFusion® drug delivery platform after struggling for years with a severe hospital-acquired skin infection.
Since its establishment, Turn Therapeutics has expanded, now led by an experienced leadership team and supported by a scientific advisory board composed of experts in inflammatory skin diseases and cytokine biology.
The moderate-to-severe eczema market is dominated by systemic therapies, including oral and injectable options.
A topical, non-systemic cytokine-modulating treatment that clinically demonstrates rapid onset and delivers safe, effective reductions in inflammation and pruritus would offer clear differentiation from currently marketed products and establish a new therapeutic category with broad patient appeal.
